GTC Biotherapeutics (fka GTCB)

[mblimon]

Apart from the phrase at the end where psoriasis is still mentioned as being in clinical development (see ThomasS), there is also another phrase where psoriasis is still mentioned.

"We continue to view MM-093 as a novel and highly differentiated therapeutic that could have a significant impact in the treatment of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, uveitis, inflammatory bowel disease and psoriasis, among others."

True, it is remarkable, that psoriasis is missing where you indicated. But it is not enough to write it off IMO.